𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effects of bortezomib on bone disease in multiple myeloma

✍ Scribed by Matthew T. Drake; S. Vincent Rajkumar

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
52 KB
Volume
84
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Biochemical markers of bone turnover in
Biochemical markers of bone turnover in diagnosis of myeloma bone disease
✍ Omer Dizdar; Ibrahim Barista; Umut Kalyoncu; Omer Karadag; Gulsen Hascelik; Ayse πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 174 KB πŸ‘ 1 views

## Abstract This study was designed to explore the value of markers of bone turnover, macrophage inflammatory protein‐1Ξ± (MIP‐1Ξ±), and osteopontin (OPN) in the diagnosis of myeloma bone disease. Twenty‐five patients with newly diagnosed and untreated multiple myeloma (MM), and 22 age‐, sex‐, and bo

Mechanisms of bone lesions in multiple m
Mechanisms of bone lesions in multiple myeloma and lymphoma
✍ G. David Roodman πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 159 KB πŸ‘ 1 views

virus-1 (HTLV-1) virus. The primary mechanism for bone destruction in patients Antonio, Texas. with myeloma and lymphoma is increased osteoclastic bone resorption. In patients with multiple myeloma, new bone formation is also inhibited. Mediators including lymphotoxin, interleukin-1b, parathyroid h

Pulmonary fibrosis in a myeloma patient
Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug
✍ Adrian Duek; Edith Feldberg; Michal Haran; Alain Berrebi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 314 KB πŸ‘ 1 views

To the Editor: A 42-year-old Chinese woman suffered from acute lymphoblastic leukemia (ALL) with t(9;22) and achieved complete remission with induction chemotherapy without imatinib mesylate (STI-571). She had one 40-year-old HLA identical sister from Fujian province, China. However, repeated human